Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Ipilimumab
Related studies linked through entity extraction aliases.
Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Phase I/II Study of Intratumoral Injection of SD-101
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Ipilimumab and Stereotactic Body Radiation Therapy (SBRT) in Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
- Status
- COMPLETED
- Phase
- PHASE3
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
YERVOY® Risk Minimization Tool Effectiveness Evaluation Survey
- Status
- COMPLETED
- Phase
- N/A
Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- EARLY_PHASE1
Adoptive Therapy Using Antigen-Specific CD4 T-Cells
- Status
- WITHDRAWN
- Phase
- PHASE1
High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery
- Status
- TERMINATED
- Phase
- PHASE2
Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic Melanoma
- Status
- NO_LONGER_AVAILABLE
- Phase
- N/A
A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery
- Status
- COMPLETED
- Phase
- PHASE2
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer
- Status
- COMPLETED
- Phase
- N/A
Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma
- Status
- COMPLETED
- Phase
- PHASE1
Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma
- Status
- COMPLETED
- Phase
- PHASE1
GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain Metastases
- Status
- COMPLETED
- Phase
- PHASE2
T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma
- Status
- COMPLETED
- Phase
- PHASE2